Login to Your Account



Financings Roundup

Celldex Raises $31M, Gears Up for Phase III Trial of GBM Drug

By Jennifer Boggs


Thursday, May 19, 2011
Finalizing the design for its planned pivotal trial of cancer vaccine rindopepimut (CDX-110) in glioblastoma multiforme (GBM), slated to start in the second half of this year, Celldex Therapeutics Inc. padded its balance sheet with a $31.5 million public offering.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription